Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Depreciation & Amortization (CF) (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Depreciation & Amortization (CF) data on record, last reported at $816000.0 in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) changed 0.37% year-over-year to $816000.0; the TTM value through Dec 2025 reached $3.4 million, up 6.39%, while the annual FY2025 figure was $3.4 million, 6.39% up from the prior year.
  • Depreciation & Amortization (CF) reached $816000.0 in Q4 2025 per CLDX's latest filing, down from $824000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $873000.0 in Q2 2025 and bottomed at $671000.0 in Q3 2022.
  • Average Depreciation & Amortization (CF) over 5 years is $776450.0, with a median of $775000.0 recorded in 2021.
  • Peak YoY movement for Depreciation & Amortization (CF): plummeted 33.48% in 2021, then grew 14.31% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $777000.0 in 2021, then fell by 13.38% to $673000.0 in 2022, then rose by 12.78% to $759000.0 in 2023, then grew by 7.91% to $819000.0 in 2024, then dropped by 0.37% to $816000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $816000.0 in Q4 2025, $824000.0 in Q3 2025, and $873000.0 in Q2 2025.